Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Higher levels of leisure-time physical activity cut the risk of cardiovascular and all-cause mortality in people with type 2 diabetes….
Read More »EASD: Once a Year Exenatide Introduced at EASD
Continuous long-term delivery of exenatide with Intarcia’s osmotic mini-pump system allows optimal dose selection for improved glycemic control, ensures adherence, and improves patient tolerability….
Read More »EASD: Merck’s Investigational Once-Weekly DPP-4 Inhibitor Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
Merck announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes….
Read More »EASD: Kidneys Tell of Heart Risk in Type 1 Diabetes
Researchers report that, for type 1 diabetes patients who have good glycemic control, renal function may predict their risk of developing heart disease….
Read More »EASD: SGLT-2 Demonstrates Reductions in Blood Pressure
Analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes…. Boehringer Ingelheim and Eli Lilly announced data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) …
Read More »EASD: SGLT-2 Added to Insulin Effective or Type 2’s with CVD
First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease…. Canagliflozin was also shown to be effective and generally well-tolerated in patients with type 2 diabetes aged 55 to …
Read More »EASD: Findings Presented on New Insulin Sensitizing Agent for Treatment of Type 2 Diabetes
Researchers have identified a mitochondrial target through which insulin sensitizers achieve their anti-diabetic effects….
Read More »EASD: Lilly and Boehringer Ingelheim Present Data for Investigational Novel Basal Insulin Analog
Eli Lilly and Boehringer Ingelheim announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes….
Read More »Electronic Health Records Linked to Better Diabetes Outcomes
The use of an outpatient electronic health record (EHR) system, rolled out across 17 medical centers, was associated with improvements in clinical outcomes and health care utilization in a study population of nearly 170,000 people with diabetes….
Read More »Kidney Disease a Predictor of Mortality
Kidney disease is a significant predictor of all-cause mortality and end-stage renal disease (ESRD) in patients with and without hypertension or diabetes, according to two large meta-analyses….
Read More »